VU0467319 (Compound VU319) is a highly selective and blood-brain-permeable, orally active M1 positive allosteric modulator (PAM) ( EC 50: 492 nM). VU0467319 is selective ( EC 50 > 30 μM) versus M2-5 for both human and rat. VU0467319 improves cognitive impairment in Alzheimer's disease (AD) through central M1 muscarinic receptors. VU0467319 does not induce cholinergic adverse reactions and has potential in AD research [1].
References:
[1]. Poslunsey MS, et al. Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials. ACS Chem Neurosci. 2025 Jan 1;16(1):95-107.
References:
[1]. Poslunsey MS, et al. Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials. ACS Chem Neurosci. 2025 Jan 1;16(1):95-107.
















